These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2163451)

  • 1. Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modifications.
    Freidinger RM; Williams PD; Tung RD; Bock MG; Pettibone DJ; Clineschmidt BV; DiPardo RM; Erb JM; Garsky VM; Gould NP
    J Med Chem; 1990 Jul; 33(7):1843-5. PubMed ID: 2163451
    [No Abstract]   [Full Text] [Related]  

  • 2. Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide.
    Bock MG; DiPardo RM; Williams PD; Pettibone DJ; Clineschmidt BV; Ball RG; Veber DF; Freidinger RM
    J Med Chem; 1990 Sep; 33(9):2321-3. PubMed ID: 2167976
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product.
    Williams PD; Bock MG; Tung RD; Garsky VM; Perlow DS; Erb JM; Lundell GF; Gould NP; Whitter WL; Hoffman JB
    J Med Chem; 1992 Oct; 35(21):3905-18. PubMed ID: 1331448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A structurally unique, potent, and selective oxytocin antagonist derived from Streptomyces silvensis.
    Pettibone DJ; Clineschmidt BV; Anderson PS; Freidinger RM; Lundell GF; Koupal LR; Schwartz CD; Williamson JM; Goetz MA; Hensens OD
    Endocrinology; 1989 Jul; 125(1):217-22. PubMed ID: 2544402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin receptors in human pregnant myometrium and decidua: interactions with oxytocin and vasopressin agonists and antagonists.
    Ivanisevic M; Behrens O; Helmer H; Demarest K; Fuchs AR
    Am J Obstet Gynecol; 1989 Dec; 161(6 Pt 1):1637-43. PubMed ID: 2557763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformationally constrained o-tolylpiperazine camphorsulfonamide oxytocin antagonists. Structural modifications that provide high receptor affinity and suggest a bioactive conformation.
    Williams PD; Ball RG; Clineschmidt BV; Culberson JC; Erb JM; Freidinger RM; Pawluczyk JM; Perlow DS; Pettibone DJ; Veber DF
    Bioorg Med Chem; 1994 Sep; 2(9):971-85. PubMed ID: 7712132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No requirements of cyclic conformation of antagonists in binding to vasopressin receptors.
    Manning M; Przybylski JP; Olma A; Klis WA; Kruszynski M; Wo NC; Pelton GH; Sawyer WH
    Nature; 1987 Oct 29-Nov 4; 329(6142):839-40. PubMed ID: 2959865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 125I-d(CH2)5[Tyr(Me)2, Tyr(NH2)9]AVP: iodination and binding characteristics of a vasopressin receptor ligand.
    Elands J; Barberis C; Jard S; Lammek B; Manning M; Sawyer WH; de Kloet ER
    FEBS Lett; 1988 Mar; 229(2):251-5. PubMed ID: 2964381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadal steroids regulate oxytocin receptors but not vasopressin receptors in the brain of male and female rats. An autoradiographical study.
    Tribollet E; Audigier S; Dubois-Dauphin M; Dreifuss JJ
    Brain Res; 1990 Mar; 511(1):129-40. PubMed ID: 2158853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational restriction of angiotensin II: cyclic analogues having high potency.
    Spear KL; Brown MS; Reinhard EJ; McMahon EG; Olins GM; Palomo MA; Patton DR
    J Med Chem; 1990 Jul; 33(7):1935-40. PubMed ID: 2362273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synthesis of a new class of oxytocin antagonists.
    Wiśniewski K; Trojnar J; Riviere P; Haigh R; Yea C; Ashworth D; Melin P; Nilsson A
    Bioorg Med Chem Lett; 1999 Oct; 9(19):2801-4. PubMed ID: 10522694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [3H]-[Thr4,Gly7]OT: a highly selective ligand for central and peripheral OT receptors.
    Elands J; Barberis C; Jard S
    Am J Physiol; 1988 Jan; 254(1 Pt 1):E31-8. PubMed ID: 2827511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of cyclic and linear peptide antagonists of vasopressin and oxytocin: current status and future directions.
    Manning M; Chan WY; Sawyer WH
    Regul Pept; 1993 Apr; 45(1-2):279-83. PubMed ID: 8511357
    [No Abstract]   [Full Text] [Related]  

  • 14. Design of novel bicyclic analogues derived from a potent oxytocin antagonist.
    Flouret G; Chaloin O; Borovickova L; Slaninová J
    J Pept Sci; 2006 Jun; 12(6):412-9. PubMed ID: 16432806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxytocin receptors from LLC-PK1 cells: expression in Xenopus oocytes.
    Cantau B; Barjon JN; Chicot D; Baskevitch PP; Jard S
    Am J Physiol; 1990 Apr; 258(4 Pt 2):F963-72. PubMed ID: 2158746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-peptide oxytocin agonists.
    Pitt GR; Batt AR; Haigh RM; Penson AM; Robson PA; Rooker DP; Tartar AL; Trim JE; Yea CM; Roe MB
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4585-9. PubMed ID: 15357997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxytocin and vasopressin binding sites in human and bovine ovaries.
    Fuchs AR; Behrens O; Helmer H; Vangsted A; Ivanisevic M; Grifo J; Barros C; Fields M
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 1):1961-7. PubMed ID: 2175150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxytocin receptors in rat adenohypophysis: evidence from radioligand binding studies.
    Antoni FA
    Endocrinology; 1986 Nov; 119(5):2393-5. PubMed ID: 3021442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist.
    Yamamura Y; Ogawa H; Chihara T; Kondo K; Onogawa T; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
    Science; 1991 Apr; 252(5005):572-4. PubMed ID: 1850553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.